| Title |
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit
|
|---|---|
| Published in |
Journal of Neuro-Oncology, November 2017
|
| DOI | 10.1007/s11060-017-2649-8 |
| Pubmed ID | |
| Authors |
William Sage, Mathew Guilfoyle, Catriona Luney, Adam Young, Rohitashwa Sinha, Donatella Sgubin, Joseph H. McAbee, Ruichong Ma, Sarah Jefferies, Rajesh Jena, Fiona Harris, Kieren Allinson, Tomasz Matys, Wendi Qian, Thomas Santarius, Stephen Price, Colin Watts |
| Abstract |
Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection. A retrospective cohort study of 260 patients who underwent 5-ALA resection of confirmed WHO 2007 Grade IV glioma between July 2009 and December 2014. Survival curves were calculated using the Kaplan-Meier method from surgery. The log-rank test was used to compare survival curves between groups. Cox regression was performed to identify variables predicting survival. A propensity score matched analysis was used to compare survival between patients who did and did not receive carmustine wafers while controlling for baseline characteristics. Propensity matched analysis showed no significant survival benefit of insertion of carmustine wafers over 5-ALA resection alone (HR 0.97 [0.68-1.26], p = 0.836). There was a trend to higher incidence of wound infection in those who received carmustine wafers (15.4 vs. 7.1%, p = 0.064). The Cox regression analysis showed that intraoperative residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced survival. Carmustine wafers have no added benefit following 5-ALA guided resection. Residual fluorescence and residual enhancing disease following resection have a negative impact on survival. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 24% |
| Student > Bachelor | 8 | 14% |
| Student > Master | 5 | 8% |
| Researcher | 4 | 7% |
| Student > Postgraduate | 3 | 5% |
| Other | 7 | 12% |
| Unknown | 18 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 34% |
| Neuroscience | 4 | 7% |
| Engineering | 4 | 7% |
| Nursing and Health Professions | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 22 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2019.
All research outputs
#1,290,109
of 23,008,860 outputs
Outputs from Journal of Neuro-Oncology
#44
of 2,987 outputs
Outputs of similar age
#28,003
of 325,280 outputs
Outputs of similar age from Journal of Neuro-Oncology
#1
of 82 outputs
Altmetric has tracked 23,008,860 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,987 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,280 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.